Tilray Brands (TLRY) Competitors $1.14 -0.04 (-2.97%) As of 09:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TLRY vs. ACB, CGC, CRON, OGI, SNDL, NAMS, KNSA, ARWR, OGN, and RXRXShould you be buying Tilray Brands stock or one of its competitors? The main competitors of Tilray Brands include Aurora Cannabis (ACB), Canopy Growth (CGC), Cronos Group (CRON), Organigram Global (OGI), SNDL (SNDL), NewAmsterdam Pharma (NAMS), Kiniksa Pharmaceuticals International (KNSA), Arrowhead Pharmaceuticals (ARWR), Organon & Co. (OGN), and Recursion Pharmaceuticals (RXRX). These companies are all part of the "pharmaceutical products" industry. Tilray Brands vs. Its Competitors Aurora Cannabis Canopy Growth Cronos Group Organigram Global SNDL NewAmsterdam Pharma Kiniksa Pharmaceuticals International Arrowhead Pharmaceuticals Organon & Co. Recursion Pharmaceuticals Aurora Cannabis (NASDAQ:ACB) and Tilray Brands (NASDAQ:TLRY) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations. Do insiders & institutionals believe in ACB or TLRY? 47.6% of Aurora Cannabis shares are owned by institutional investors. Comparatively, 9.4% of Tilray Brands shares are owned by institutional investors. 0.0% of Aurora Cannabis shares are owned by company insiders. Comparatively, 0.6% of Tilray Brands shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media prefer ACB or TLRY? In the previous week, Tilray Brands had 9 more articles in the media than Aurora Cannabis. MarketBeat recorded 26 mentions for Tilray Brands and 17 mentions for Aurora Cannabis. Tilray Brands' average media sentiment score of 0.64 beat Aurora Cannabis' score of 0.00 indicating that Tilray Brands is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aurora Cannabis 2 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Tilray Brands 11 Very Positive mention(s) 1 Positive mention(s) 11 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings and valuation, ACB or TLRY? Aurora Cannabis has higher earnings, but lower revenue than Tilray Brands. Aurora Cannabis is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAurora Cannabis$246.72M1.23$1.63M-$0.19-28.37Tilray Brands$821.31M1.58-$2.19B-$2.31-0.51 Which has more risk and volatility, ACB or TLRY? Aurora Cannabis has a beta of 1.84, suggesting that its stock price is 84% more volatile than the S&P 500. Comparatively, Tilray Brands has a beta of 1.85, suggesting that its stock price is 85% more volatile than the S&P 500. Do analysts recommend ACB or TLRY? Tilray Brands has a consensus target price of $1.92, indicating a potential upside of 62.43%. Given Tilray Brands' higher probable upside, analysts plainly believe Tilray Brands is more favorable than Aurora Cannabis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aurora Cannabis 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.00Tilray Brands 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 Is ACB or TLRY more profitable? Aurora Cannabis has a net margin of -5.66% compared to Tilray Brands' net margin of -265.69%. Aurora Cannabis' return on equity of -1.49% beat Tilray Brands' return on equity.Company Net Margins Return on Equity Return on Assets Aurora Cannabis-5.66% -1.49% -1.06% Tilray Brands -265.69%-6.83%-5.45% SummaryAurora Cannabis and Tilray Brands tied by winning 8 of the 16 factors compared between the two stocks. Get Tilray Brands News Delivered to You Automatically Sign up to receive the latest news and ratings for TLRY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TLRY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TLRY vs. The Competition Export to ExcelMetricTilray BrandsMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.38B$10.54B$5.61B$9.84BDividend YieldN/A1.94%4.61%4.07%P/E Ratio-0.5119.6430.2925.74Price / Sales1.5829.26470.66115.79Price / Cash8.6524.6838.2159.48Price / Book0.843.088.846.15Net Income-$2.19B$209.94M$3.25B$265.06M7 Day Performance81.90%6.22%3.72%2.60%1 Month Performance98.89%12.43%5.86%2.83%1 Year Performance-39.49%-8.96%30.23%25.58% Tilray Brands Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TLRYTilray Brands2.4134 of 5 stars$1.17-1.3%$1.92+64.5%-38.5%$1.29B$821.31M-0.512,842Gap DownACBAurora Cannabis0.6685 of 5 stars$4.55-1.6%N/A-21.5%$255.66M$246.72M41.321,130Gap DownCGCCanopy Growth0.682 of 5 stars$1.07-3.2%N/A-78.2%$218.49M$225.65M-0.263,150News CoveragePositive NewsEarnings ReportAnalyst UpgradeShort Interest ↑Analyst RevisionGap DownCRONCronos Group0.8726 of 5 stars$2.04+0.7%N/A+7.2%$781.05M$117.61M15.66450Gap DownOGIOrganigram Global0.605 of 5 stars$1.39+0.4%N/A-17.9%$185.63M$117.47M13.85860Earnings ReportAnalyst RevisionGap DownSNDLSNDL2.2368 of 5 stars$1.66+0.9%$4.00+141.7%-2.3%$434.90M$671.81M-6.132,516Options VolumeGap DownNAMSNewAmsterdam Pharma3.5543 of 5 stars$21.98+1.5%$41.30+87.9%+48.1%$2.45B$47.14M-11.604KNSAKiniksa Pharmaceuticals International2.6605 of 5 stars$33.03+0.2%$41.17+24.7%+30.8%$2.40B$423.24M823.96220Positive NewsInsider TradeARWRArrowhead Pharmaceuticals4.0854 of 5 stars$16.56+0.5%$43.71+164.1%-17.3%$2.28B$545.21M-11.81400News CoverageAnalyst RevisionOGNOrganon & Co.4.6988 of 5 stars$8.69-10.2%$18.00+107.3%-53.0%$2.26B$6.40B3.024,000RXRXRecursion Pharmaceuticals1.4844 of 5 stars$5.53-4.7%$7.00+26.7%-10.2%$2.25B$58.84M-3.12400 Related Companies and Tools Related Companies ACB Competitors CGC Competitors CRON Competitors OGI Competitors SNDL Competitors NAMS Competitors KNSA Competitors ARWR Competitors OGN Competitors RXRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TLRY) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tilray Brands, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tilray Brands With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access